Biogen shares plunge after company makes change to Alzheimer ’s drug trials

Biogen said Wednesday that it will increase the size of trials of its experimental Alzheimer ’s drug after early data showed “variability” in the data, sending shares of the Cambridge company down sharply. A spokesperson for Biogen (Nasdaq: BIIB) said the company had decided to increase the sample size of two closely watched trials by 510 patients, to a total of 3,210 patients, confi rming remarks by the company’s chief medical officer during a healthcare conference earlier on Wednesday afternoon.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news